Vor Biopharma Inc. (VOR) Current Ratio
- Current ratio · latest quarter: Value 19.15×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 19.15× | Current assets / current liabilities. $475.11M ÷ $24.81M ≈ 19.15× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 475.11M USD | Assets, Current |
| Current obligations | 24.81M USD | Liabilities, Current |
| Cash and equivalents | 107.86M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 358.27M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 4.00M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $475.11M | $24.81M | $107.86M | $358.27M | (m) | (m) | $4.00M | (m) | 19.15× |
| 2026-03-31 | $500.78M | $16.08M | $169.87M | $321.65M | (m) | (m) | $1.04M | (m) | 31.15× |
| 2025-12-31 | $458.11M | $25.17M | $396.49M | $58.72M | (m) | (m) | $5.13M | (m) | 18.20× |
| 2025-09-30 | $172.49M | $18.84M | $160.46M | $10.00M | (m) | (m) | $885.00K | (m) | 9.16× |
| 2025-06-30 | $204.93M | $58.77M | $190.57M | $9.99M | (m) | (m) | $669.00K | (m) | 3.49× |
| 2025-03-31 | $64.85M | $16.73M | $50.05M | $9.99M | (m) | (m) | $3.73M | (m) | 3.88× |
| 2024-12-31 | $96.51M | $18.61M | $81.95M | $9.98M | (m) | (m) | $1.50M | (m) | 5.19× |
| 2024-09-30 | $67.30M | $14.35M | $52.80M | $10.01M | (m) | (m) | $1.32M | (m) | 4.69× |
| 2024-06-30 | $90.26M | $13.80M | $76.08M | $9.86M | (m) | (m) | $2.01M | (m) | 6.54× |
| 2024-03-31 | $111.82M | $13.21M | $44.96M | $62.52M | (m) | (m) | $2.33M | (m) | 8.46× |
| 2023-12-31 | $140.80M | $15.57M | $31.36M | $105.81M | (m) | (m) | $815.00K | (m) | 9.04× |
| 2023-09-30 | $164.44M | $15.39M | $45.03M | $115.07M | (m) | (m) | $1.31M | (m) | 10.69× |
| 2023-06-30 | $191.39M | $12.72M | $32.21M | $154.69M | (m) | (m) | $1.65M | (m) | 15.05× |
| 2023-03-31 | $216.90M | $12.58M | $42.45M | $167.75M | (m) | (m) | $3.22M | (m) | 17.24× |
| 2022-12-31 | $236.95M | $13.12M | $57.71M | $172.54M | (m) | (m) | $1.77M | (m) | 18.06× |
| 2022-09-30 | $142.73M | $11.10M | $60.83M | $75.24M | (m) | (m) | $824.00K | (m) | 12.86× |
| 2022-06-30 | $158.84M | $12.26M | $62.95M | $88.14M | (m) | (m) | $1.27M | (m) | 12.95× |
| 2022-03-31 | $190.30M | $18.14M | $90.04M | $91.58M | (m) | (m) | $1.25M | (m) | 10.49× |
| 2021-12-31 | $214.40M | $10.15M | $119.80M | $87.67M | (m) | (m) | $1.54M | (m) | 21.12× |
| 2021-09-30 | $232.07M | $9.21M | $143.03M | (m) | (m) | (m) | $1.96M | (m) | 25.20× |
| 2021-06-30 | $249.26M | $8.30M | $169.52M | (m) | (m) | (m) | $2.37M | (m) | 30.02× |
| 2021-03-31 | $266.26M | $8.63M | $262.57M | (m) | (m) | (m) | $2.41M | (m) | 30.85× |
| 2020-12-31 | $49.11M | $10.21M | $48.54M | (m) | (m) | (m) | $2.36M | (m) | 4.81× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |